Skip to main content
. Author manuscript; available in PMC: 2011 Oct 6.
Published in final edited form as: Int J Urol. 2010 Sep 30;17(11):914–922. doi: 10.1111/j.1442-2042.2010.02631.x

Table 4.

Concordance indexes of various models for predicting biochemical recurrence among patients with undetectable and detectable prostate-specific antigen (PSA) nadir in the Shared Equal Access Regional Cancer Hospital (SEARCH) cohort

Model Undetectable PSA nadir
 Detectable PSA nadir
CI N R CI N R
Preoperative models
 d'Amico 0.635 607 96 0.618 275 78
 CAPRA 0.687 562 85 0.671 242 72
 Preoperative Kattan 0.660 593 94 0.649 266 78
Postoperative models
 PSA nadir alone – – – 0.745 289 69
 Postoperative Kattan 0.729 572 87 0.708 254 68
 DPC 0.706 591 92 0.731 252 70
 CPDR 0.666 607 97 0.684 267 74
 JHH 0.695 577 88 0.694 265 72
 PSA nadir nomogram 0.720 632 89 0.790 289 69

CAPRA, Cancer of the Prostate Risk Assessment; CI, concordance index; CPDR, Center for Prostate Disease Research; DPC, Duke Prostate Center; JHH, Johns Hopkins Hospital; N, number of subjects; R, number of recurrences.